X0508 4 2026-02-02 0001750284 Olema Pharmaceuticals, Inc. OLMA 0001831218 Bohen Sean C/O OLEMA PHARMACEUTICALS, INC. 780 BRANNAN ST SAN FRANCISCO CA 94103 true true false false PRESIDENT AND CEO 0 Stock Option (Right to Buy) 25.65 2026-02-02 4 A 0 850000 0 A 2036-02-01 Common Stock 850000 850000 D Performance Stock Options (Right to Buy) 25.65 2026-02-02 4 A 0 275000 0 A 2036-02-01 Common Stock 275000 275000 D 25% of the shares subject to the option vest on February 2, 2027, and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. The performance-based stock options will be eligible to vest during two distinct performance periods, each beginning on February 2, 2026 and ending on December 31, 2029 and December 31, 2030, respectively, based on the Issuer's stock price trading at certain pre-determined price thresholds as measured by the average closing price per share of the Issuer's stock over a consecutive thirty (30) day trading period during each such performance period. Once a price threshold is achieved, the portion of the award related to such threshold will vest upon the date set forth in the certification by the Compensation Committee certifying that such price threshold was achieved, subject to the Reporting Person's continuous service as of the applicable certification date. Notwithstanding the foregoing, if the Reporting Person's continuous service is terminated without Cause (as defined in the Reporting Person's offer letter), the performance-based stock options shall remain outstanding and eligible to vest for twelve (12) months following such termination. /s/ Shawnte Mitchell, Attorney-in-Fact 2026-02-04